Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
Authors:
- O. PaganiO. Pagani
- A. BuonadonnaA. Buonadonna
- B. ThürlimannBTB. Thürlimann
- D. HessDHD. Hess
Open Access
- 1 May 1999
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 10 (5) , 539-546
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.Journal of Clinical Oncology, 1997
- Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.Journal of Clinical Oncology, 1997
- Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.Journal of Clinical Oncology, 1996
- Paclitaxel induces significant changes in epidoxorubicin distribution in miceAnnals of Oncology, 1996
- First-line treatment of metastatic breast cancerAnti-Cancer Drugs, 1996
- Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial.Journal of Clinical Oncology, 1993
- Management of Fever in Patients with Cancer and Treatment-Induced NeutropeniaNew England Journal of Medicine, 1993
- Systemic Therapy of Advanced Breast CancerDrugs, 1992
- Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin.Journal of Clinical Oncology, 1988
- Reporting results of cancer treatmentCancer, 1981